Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Apoptosis
Research from Zhejiang University in the area of apoptosis published
August 12th, 2008
According to a study from Hangzhou, People's Republic of China, "Hepatocellular carcinoma (HCC) is the most common malignancy of the liver. It is unfortunate that HCCs are highly refractory to conventional chemotherapy, radiation therapy, and even immunotherapy." "Thus, novel therapeutic targets need to be sought for the successful treatment of HCCs. We now report that (+/-)-(3aRS, 4SR)-2-(2-chloro-4-methylsulfonylphenyl)-4'-chloro-3 alpha, 4-diethoxy-flavane[4,3-d]-D1,9b-1,2,3-thiadiazoline (MSFTZ), a synthesized flavanone derivative, induced growth arrest and apoptosis of HCCs both in vitro and in vivo. MSFTZ induced a time-and dose-dependent increase in HCC apoptosis...
Source: Cancer Weekly (2008-08-12)
|
